A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)
Latest Information Update: 14 Mar 2025
At a glance
- Drugs Ruxoprubart (Primary) ; Azathioprine; Corticosteroids; Cyclophosphamide; Rituximab
- Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Granulomatosis with polyangiitis; Microscopic polyangiitis; Vasculitis
- Focus Therapeutic Use
- Sponsors NovelMed Therapeutics
Most Recent Events
- 11 Mar 2025 Planned End Date changed from 1 Sep 2027 to 1 Sep 2028.
- 11 Mar 2025 Planned primary completion date changed from 1 Oct 2026 to 1 Oct 2027.
- 11 Mar 2025 Planned initiation date changed from 1 Jun 2025 to 1 Jun 2026.